drugset

drugset / Trial / NCT06131216

Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors

NCT06131216 ↗

Phase 1 Not yet recruiting 116 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of SHR-2022 in patients with advanced malignancies and to determine MTD or MAD versus RP2D

Timeline

Start: 2023-12
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-2022	Unknown	—	Intravenous

Indications